Tumor Stage as A Determinant of Treatment-Related Toxicity in Laryngeal Cancer: A Retrospective Cohort Study at the National Institute of Oncology, Rabat
TL;DR
Evaluating the association between tumor stage and treatment-related toxicity in patients treated for laryngeal cancer at the National Institute of Oncology in Rabat between January 2022 and January 2024 found no clear link between tumor stage and treatment-related toxicity.
Abstract
Background: Laryngeal cancer is one of the most common malignancies of the upper aerodigestive tract. Its management relies on surgery, radiotherapy, chemotherapy, or combined treatment modalities according to tumor stage. Although current therapeutic strategies have improved locoregional control and organ preservation, treatment-related toxicity remains a major clinical concern, particularly among patients with locally advanced disease. This study aimed to evaluate the association between tumor stage and treatment-related toxicity in patients treated for laryngeal cancer at the National Institute of Oncology in Rabat. Methods: We conducted a retrospective cohort study including patients with histologically confirmed laryngeal cancer treated at the Department of Radiation Oncology of the National Institute of Oncology, Rabat, between January 2022 and January 2024. Clinical, tumor-related, treatment-related, and toxicity data were collected from medical records. Tumor stage was determined according to the TNM classification, and patients were categorized into two groups: early-stage disease and locally advanced disease. Acute and late toxicities were assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The association between tumor stage and treatment-related toxicity was analyzed using comparative statistical tests. Results: A total of 127 patients were included. The median age was 56 years, with a marked male predominance. Most patients presented with locally advanced disease at diagnosis.